Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585195 · ClinicalTrials.gov registry record · Phase 1
A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 596
- Enrollment target
NCT00585195 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 596 participants.
The verdict
NCT00585195, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 596 participants
- Enrollment target
Study Summary
PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG PF-02341066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 596 participants |
| Start Date | 2006-04-19 |
| Est. Completion | 2022-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585195
The ClinicalTrials.gov registry entry for NCT00585195 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 596 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT00585195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00585195 about?
NCT00585195 is a clinical study titled "A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer". PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine...
What is the current status of trial NCT00585195?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 596 participants. The study started on 2006-04-19. Estimated completion is 2022-01-19.
What interventions are being tested in trial NCT00585195?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), PF-02341066 (DRUG).
Who is sponsoring clinical trial NCT00585195?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.